Ignite Creation Date:
2025-12-24 @ 11:45 PM
Ignite Modification Date:
2026-01-01 @ 12:41 PM
Study NCT ID:
NCT05257551
Status:
RECRUITING
Last Update Posted:
2025-05-06
First Post:
2022-01-20
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Tempus Sculptor Study: Small Cell Lung Cancer (SCLC) Observational Study
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D055752', 'term': 'Small Cell Lung Carcinoma'}, {'id': 'D009369', 'term': 'Neoplasms'}], 'ancestors': [{'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}, {'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D019370', 'term': 'Observation'}], 'ancestors': [{'id': 'D008722', 'term': 'Methods'}, {'id': 'D008919', 'term': 'Investigative Techniques'}]}}, 'protocolSection': {'designModule': {'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'Blood and tissue samples will be collected'}, 'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'CASE_ONLY'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 50}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2022-07-13', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-05', 'completionDateStruct': {'date': '2026-03', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-05-05', 'studyFirstSubmitDate': '2022-01-20', 'studyFirstSubmitQcDate': '2022-02-17', 'lastUpdatePostDateStruct': {'date': '2025-05-06', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2022-02-25', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-03', 'type': 'ESTIMATED'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'To measure biomarkers of SCLC using the TEMPUS xT assay', 'timeFrame': 'Up to 4 years', 'description': 'To measure specific biomarkers of SCLC subtypes and outcomes using the TEMPUS xT assay'}, {'measure': 'To identify biomarkers and mechanisms of progression', 'timeFrame': 'Up to 4 years', 'description': 'To identify biomarkers and mechanisms of progression from EP + PDL1-i therapy'}, {'measure': 'To study progression free survival (PFS) and overall survival (OS)', 'timeFrame': 'Up to 4 years', 'description': 'To study real-world PFS and OS as measured by the treating clinician'}], 'primaryOutcomes': [{'measure': 'To determine if tumor tissue transcriptional subtypes can be detected', 'timeFrame': 'Up to 4 years', 'description': 'To determine prospectively if SCLC tumor tissue transcriptional subtypes can be detected by Tempus\\|xT RNAseq'}, {'measure': 'To characterize relationship between tissue transcriptional subtype and clinical outcomes', 'timeFrame': 'Up to 4 years', 'description': 'To characterize the relationship between tissue transcriptional subtype and clinical outcomes for EP+PDL1-i therapy based on collection of longitudinal information from medical records'}], 'secondaryOutcomes': [{'measure': 'To assess the potential for liquid biopsy in SCLC', 'timeFrame': 'Up to 4 years', 'description': 'To use blood based assays to assess the complementarity of circulating biomarkers to tissue based methods'}, {'measure': 'To test which tissue and sample variables confound gene expression subtypes', 'timeFrame': 'Up to 4 years', 'description': 'To measure how variable transcriptional measurements are across tissue characteristics such as site of biopsy and type of biopsy'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Cancer', 'Oncology', 'Observational', 'Genomic Profiling', 'Precision medicine', 'SCLC', 'Small Cell Lung Cancer', 'NGS', 'Biomarkers', 'ctDNA', 'Transcriptomics'], 'conditions': ['Small Cell Lung Cancer']}, 'referencesModule': {'references': [{'pmid': '4972690', 'type': 'BACKGROUND', 'citation': 'Ghosh S, Bilton JL. Torsion and infarction of the appendices epiploicae: Report of five cases. Dis Colon Rectum. 1968 Nov;11(6):457-61. doi: 10.1007/BF02616778. No abstract available.'}, {'pmid': '5497465', 'type': 'BACKGROUND', 'citation': 'Khondkarian OA, Zavalishin IA. [Several characteristics of "pyramid" insufficiency in lateral amyotrophic sclerosis]. Klin Med (Mosk). 1970 Sep;48(9):93-6. No abstract available. Russian.'}, {'pmid': '8628860', 'type': 'BACKGROUND', 'citation': 'van Beek EJ, Bakker AJ, Reekers JA. Pulmonary embolism: interobserver agreement in the interpretation of conventional angiographic and DSA images in patients with nondiagnostic lung scan results. Radiology. 1996 Mar;198(3):721-4. doi: 10.1148/radiology.198.3.8628860.'}, {'pmid': '23836314', 'type': 'BACKGROUND', 'citation': 'Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013 Aug;10(8):472-84. doi: 10.1038/nrclinonc.2013.110. Epub 2013 Jul 9.'}, {'pmid': '32513672', 'type': 'BACKGROUND', 'citation': 'Drapkin BJ, Rudin CM. Advances in Small-Cell Lung Cancer (SCLC) Translational Research. Cold Spring Harb Perspect Med. 2021 Apr 1;11(4):a038240. doi: 10.1101/cshperspect.a038240.'}, {'pmid': '33482121', 'type': 'BACKGROUND', 'citation': 'Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, Nabet BY, Fujimoto J, Solis LM, Lu W, Xi Y, Cardnell RJ, Wang Q, Fabbri G, Cargill KR, Vokes NI, Ramkumar K, Zhang B, Della Corte CM, Robson P, Swisher SG, Roth JA, Glisson BS, Shames DS, Wistuba II, Wang J, Quaranta V, Minna J, Heymach JV, Byers LA. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021 Mar 8;39(3):346-360.e7. doi: 10.1016/j.ccell.2020.12.014. Epub 2021 Jan 21.'}, {'pmid': '33285097', 'type': 'BACKGROUND', 'citation': 'Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Ozguroglu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L; CASPIAN investigators. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4.'}, {'pmid': '30280641', 'type': 'BACKGROUND', 'citation': 'Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25.'}, {'pmid': '30323087', 'type': 'BACKGROUND', 'citation': 'Kalemkerian GP, Loo BW, Akerley W, Attia A, Bassetti M, Boumber Y, Decker R, Dobelbower MC, Dowlati A, Downey RJ, Florsheim C, Ganti AKP, Grecula JC, Gubens MA, Hann CL, Hayman JA, Heist RS, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran CA, Morgensztern D, Pokharel S, Portnoy DC, Rhodes D, Rusthoven C, Sands J, Santana-Davila R, Williams CC, Hoffmann KG, Hughes M. NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018. J Natl Compr Canc Netw. 2018 Oct;16(10):1171-1182. doi: 10.6004/jnccn.2018.0079.'}, {'pmid': '33506766', 'type': 'BACKGROUND', 'citation': 'Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV; CCGA Consortium. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020 Jun;31(6):745-759. doi: 10.1016/j.annonc.2020.02.011. Epub 2020 Mar 30.'}, {'pmid': '33707236', 'type': 'BACKGROUND', 'citation': 'Mahadevan NR, Knelson EH, Wolff JO, Vajdi A, Saigi M, Campisi M, Hong D, Thai TC, Piel B, Han S, Reinhold BB, Duke-Cohan JS, Poitras MJ, Taus LJ, Lizotte PH, Portell A, Quadros V, Santucci AD, Murayama T, Canadas I, Kitajima S, Akitsu A, Fridrikh M, Watanabe H, Reardon B, Gokhale PC, Paweletz CP, Awad MM, Van Allen EM, Lako A, Wang XT, Chen B, Hong F, Sholl LM, Tolstorukov MY, Pfaff K, Janne PA, Gjini E, Edwards R, Rodig S, Reinherz EL, Oser MG, Barbie DA. Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity. Cancer Discov. 2021 Aug;11(8):1952-1969. doi: 10.1158/2159-8290.CD-20-0913. Epub 2021 Mar 11.'}, {'pmid': '28855354', 'type': 'BACKGROUND', 'citation': 'Ooki A, Maleki Z, Tsay JJ, Goparaju C, Brait M, Turaga N, Nam HS, Rom WN, Pass HI, Sidransky D, Guerrero-Preston R, Hoque MO. A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non-Small Cell Lung Cancer and Serum DNA. Clin Cancer Res. 2017 Nov 15;23(22):7141-7152. doi: 10.1158/1078-0432.CCR-17-1222. Epub 2017 Aug 29.'}, {'pmid': '34663914', 'type': 'BACKGROUND', 'citation': 'Rekhtman N. Lung neuroendocrine neoplasms: recent progress and persistent challenges. Mod Pathol. 2022 Jan;35(Suppl 1):36-50. doi: 10.1038/s41379-021-00943-2. Epub 2021 Oct 18.'}, {'pmid': '34162872', 'type': 'BACKGROUND', 'citation': 'Roper N, Velez MJ, Chiappori A, Kim YS, Wei JS, Sindiri S, Takahashi N, Mulford D, Kumar S, Ylaya K, Trindade C, Manukyan I, Brown AL, Trepel JB, Lee JM, Hewitt S, Khan J, Thomas A. Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer. Nat Commun. 2021 Jun 23;12(1):3880. doi: 10.1038/s41467-021-24164-y.'}, {'pmid': '30926931', 'type': 'BACKGROUND', 'citation': 'Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, Heymach JV, Johnson JE, Lehman JM, MacPherson D, Massion PP, Minna JD, Oliver TG, Quaranta V, Sage J, Thomas RK, Vakoc CR, Gazdar AF. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019 May;19(5):289-297. doi: 10.1038/s41568-019-0133-9.'}, {'pmid': '31912902', 'type': 'BACKGROUND', 'citation': 'Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.'}, {'pmid': '28252003', 'type': 'BACKGROUND', 'citation': 'Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017 Sep;14(9):531-548. doi: 10.1038/nrclinonc.2017.14. Epub 2017 Mar 2.'}, {'pmid': '33521652', 'type': 'BACKGROUND', 'citation': 'Stewart CA, Gay CM, Xi Y, Sivajothi S, Sivakamasundari V, Fujimoto J, Bolisetty M, Hartsfield PM, Balasubramaniyan V, Chalishazar MD, Moran C, Kalhor N, Stewart J, Tran H, Swisher SG, Roth JA, Zhang J, de Groot J, Glisson B, Oliver TG, Heymach JV, Wistuba I, Robson P, Wang J, Byers LA. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nat Cancer. 2020 Apr;1:423-436. doi: 10.1038/s43018-019-0020-z. Epub 2020 Feb 17.'}, {'pmid': '33086069', 'type': 'BACKGROUND', 'citation': 'Tlemsani C, Pongor L, Elloumi F, Girard L, Huffman KE, Roper N, Varma S, Luna A, Rajapakse VN, Sebastian R, Kohn KW, Krushkal J, Aladjem MI, Teicher BA, Meltzer PS, Reinhold WC, Minna JD, Thomas A, Pommier Y. SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures. Cell Rep. 2020 Oct 20;33(3):108296. doi: 10.1016/j.celrep.2020.108296.'}, {'pmid': '31217577', 'type': 'BACKGROUND', 'citation': 'Zepp JA, Morrisey EE. Cellular crosstalk in the development and regeneration of the respiratory system. Nat Rev Mol Cell Biol. 2019 Sep;20(9):551-566. doi: 10.1038/s41580-019-0141-3. Epub 2019 Jun 19.'}, {'pmid': '29535911', 'type': 'BACKGROUND', 'citation': 'Zhang W, Girard L, Zhang YA, Haruki T, Papari-Zareei M, Stastny V, Ghayee HK, Pacak K, Oliver TG, Minna JD, Gazdar AF. Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes. Transl Lung Cancer Res. 2018 Feb;7(1):32-49. doi: 10.21037/tlcr.2018.02.02.'}, {'type': 'BACKGROUND', 'citation': 'Howlader, Nnam, A. M. Noone, Me Krapcho, D. Miller, A. Brest, M. Yu, J. Ruhl, et al. 2020."SEER Cancer Statistics Review, 1975--2017." National Cancer Institute.'}]}, 'descriptionModule': {'briefSummary': 'The study is a non-interventional evaluation of participants with SCLC who will receive diagnostic and (where possible) post-progression tumor tissue profiling, alongside plasma ctDNA biomarker profiling in addition to their standard of care therapy and disease surveillance.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'This protocol targets patients with Small Cell Lung Cancer (SCLC)', 'healthyVolunteers': False, 'eligibilityCriteria': 'The following are the inclusion criteria. Participants are eligible to be included in this study only if all the following criteria apply. The participant has/is:\n\n* Histologically confirmed small cell lung cancer diagnosis\n* Diagnosis made with excisional or core needle biopsy specimen (fine needle aspirate may be permitted with approval from the PI)\n* Subjects must submit fresh or archived FFPE tumor sample to the central laboratory\n* ECOG performance status of 0-2 at time of enrollment\n* Planned extensive stage first-line therapy of etoposide plus carboplatin plus PD-L1 inhibitor (atezolizumab or durvalumab)\n* Extensive stage disease at time of diagnosis\n* Willing and able to provide informed consent\n* Radiotherapy is permitted as long as there is measurable disease outside of the radiotherapy port\n\nParticipants will be excluded from the study if any of the following criteria apply. The participant has/is:\n\n* History of prior systemic treatment of SCLC\n* Prior diagnosis of non-small cell lung cancer is excluded if the cancer is diagnosed \\< 3 years prior to study entry. Additionally, the participant must be off all therapy for the NSCLC at the time of study entry.\n* Mixed small cell and non-small cell histology\n* Suspected metastatic cancer from other sites (i.e., those without a known or suspected lung primary diagnosis)\n* Not willing to have additional blood samples collected'}, 'identificationModule': {'nctId': 'NCT05257551', 'briefTitle': 'Tempus Sculptor Study: Small Cell Lung Cancer (SCLC) Observational Study', 'organization': {'class': 'INDUSTRY', 'fullName': 'Tempus AI'}, 'officialTitle': 'Tempus Small Cell Lung Cancer Observational Study (Sculptor): A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients With Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays', 'orgStudyIdInfo': {'id': 'TP-CA-003'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Patients with Small Cell Lung Cancer (SCLC)', 'description': 'This protocol will include participants with newly diagnosed extensive stage (stage IV) small cell lung cancer with tissue collected from the primary lung tumor, or metastatic sites outside of the liver or biliary system.', 'interventionNames': ['Other: Observation']}], 'interventions': [{'name': 'Observation', 'type': 'OTHER', 'description': 'No intervention', 'armGroupLabels': ['Patients with Small Cell Lung Cancer (SCLC)']}]}, 'contactsLocationsModule': {'locations': [{'zip': '90720', 'city': 'Los Alamitos', 'state': 'California', 'status': 'WITHDRAWN', 'country': 'United States', 'facility': 'Cancer and Blood Specialty Clinic', 'geoPoint': {'lat': 33.80307, 'lon': -118.07256}}, {'zip': '80045', 'city': 'Aurora', 'state': 'Colorado', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Evelina Reventaite', 'role': 'CONTACT', 'phone': '303-724-9677'}, {'name': 'Tejas Patil, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Colorado', 'geoPoint': {'lat': 39.72943, 'lon': -104.83192}}, {'zip': '61615', 'city': 'Peoria', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Ashton Todd-Hitchcock', 'role': 'CONTACT', 'phone': '309-243-3000'}, {'name': 'Mohammad (Fahad) Asad, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Illinois Cancer Care', 'geoPoint': {'lat': 40.69365, 'lon': -89.58899}}, {'zip': '21287', 'city': 'Baltimore', 'state': 'Maryland', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Jenna Los', 'role': 'CONTACT', 'phone': '410-955-5288'}, {'name': 'Lonny Yarmus, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Johns Hopkins University', 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}}, {'zip': '07631', 'city': 'Englewood', 'state': 'New Jersey', 'status': 'WITHDRAWN', 'country': 'United States', 'facility': 'Englewood Health Medical Center', 'geoPoint': {'lat': 40.89288, 'lon': -73.97264}}, {'zip': '27599', 'city': 'Chapel Hill', 'state': 'North Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Ashley Delgado', 'role': 'CONTACT', 'email': 'ashley_delgado@med.unc.edu', 'phone': '984-520-7329'}, {'name': 'Jason Akulian, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of North Carolina', 'geoPoint': {'lat': 35.9132, 'lon': -79.05584}}, {'zip': '45220', 'city': 'Cincinnati', 'state': 'Ohio', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Wayne Thompson', 'role': 'CONTACT', 'phone': '513-865-5020'}, {'name': 'James Maher, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'TriHealth Cancer Institute', 'geoPoint': {'lat': 39.12711, 'lon': -84.51439}}, {'zip': '43210', 'city': 'Columbus', 'state': 'Ohio', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Jennifer Moon', 'role': 'CONTACT', 'email': 'jennifer.moon@osumc.edu', 'phone': '614-293-7581'}, {'name': 'Asrar Alahmadi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Ohio State University', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'zip': '43214', 'city': 'Columbus', 'state': 'Ohio', 'status': 'WITHDRAWN', 'country': 'United States', 'facility': 'OhioHealth Research Institute', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'zip': '74146', 'city': 'Tulsa', 'state': 'Oklahoma', 'status': 'WITHDRAWN', 'country': 'United States', 'facility': 'Oklahoma Cancer Specialists and Research Institutes', 'geoPoint': {'lat': 36.15398, 'lon': -95.99277}}, {'zip': '17403', 'city': 'York', 'state': 'Pennsylvania', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Jennifer Stough', 'role': 'CONTACT'}, {'role': 'CONTACT', 'phone': '717-741-9229'}, {'name': 'Chanh Huynh, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Cancer Care Association of York', 'geoPoint': {'lat': 39.9626, 'lon': -76.72774}}], 'centralContacts': [{'name': 'Sculptor Study', 'role': 'CONTACT', 'email': 'sculptor-study@tempus.com', 'phone': '833-514-4187'}], 'overallOfficials': [{'name': 'Virginia Rhodes, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Tempus AI, Inc.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Tempus AI', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'AstraZeneca', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}